GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx (Nasdaq: WGS), a leader in genomic insights for improved health outcomes, has announced the granting of 7,700 restricted stock units (RSUs) to two newly hired employees. The grants, effective September 23, 2024, were approved by the compensation committee of GeneDx's board of directors as inducement awards under the company's 2023 Equity Inducement Plan.
The RSUs will vest in equal annual installments over four years, contingent on continued employment. Each RSU represents the right to receive one share of GeneDx's Class A Common Stock upon settlement. This action aligns with Nasdaq Listing Rule 5635(c)(4), which allows for equity grants to new employees without shareholder approval.
GeneDx (Nasdaq: WGS), un leader nelle intuizioni genomiche per migliorare i risultati sanitari, ha annunciato l'assegnazione di 7.700 unità di azioni limitate (RSU) a due nuovi dipendenti. Le assegnazioni, efficaci dal 23 settembre 2024, sono state approvate dal comitato per la compensazione del consiglio di amministrazione di GeneDx come premi di induzione nell'ambito del Piano di Induzione Azionaria 2023 dell'azienda.
Le RSU matureranno in rate annuali uguali nell'arco di quattro anni, a condizione di un'occupazione continuativa. Ogni RSU rappresenta il diritto di ricevere un'azione della Classe A di Common Stock di GeneDx al momento del regolamento. Questa azione è in linea con il Regolamento di Quotazione Nasdaq 5635(c)(4), che consente concessioni azionarie ai nuovi dipendenti senza l'approvazione degli azionisti.
GeneDx (Nasdaq: WGS), un líder en conocimientos genómicos para mejorar los resultados de salud, ha anunciado la concesión de 7,700 unidades de acciones restringidas (RSUs) a dos empleados recién contratados. Las concesiones, con efecto a partir del 23 de septiembre de 2024, fueron aprobadas por el comité de compensación de la junta directiva de GeneDx como premios de indución bajo el Plan de Inducción de Equidad 2023 de la compañía.
Las RSUs se otorgarán en cuotas anuales iguales durante cuatro años, condicionadas a la continuidad del empleo. Cada RSU representa el derecho a recibir una acción de las Acciones Comunes Clase A de GeneDx al momento de la liquidación. Esta acción está alineada con la Regla de Listado Nasdaq 5635(c)(4), que permite concesiones de patrimonio a nuevos empleados sin la aprobación de los accionistas.
GeneDx(Nasdaq: WGS)는 건강 결과 개선을 위한 유전체 정보의 선두주자로서 두 명의 신규 채용 직원에게 7,700개의 제한주식단위(RSU)를 부여한다고 발표했습니다. 이번 부여는 2024년 9월 23일부터 효력이 생기며, GeneDx 이사회 보상 위원회에서 2023 주식 유도 계획의 유인 보상으로 승인되었습니다.
RSU는 4년 동안 매년 균등한 분할로 배분됩니다, 지속적인 고용 조건에 따라. 각 RSU는 정산 시 GeneDx의 클래스 A 보통주 1주를 받을 권리를 나타냅니다. 이 조치는 주주 승인 없이 신규 직원에게 자산 기부를 허용하는 Nasdaq 상장 규칙 5635(c)(4)와 일치합니다.
GeneDx (Nasdaq: WGS), un leader dans le domaine des connaissances génomiques pour améliorer les résultats de santé, a annoncé l'octroi de 7 700 unités d'actions restreintes (RSUs) à deux nouveaux employés. Les octrois, effectifs à partir du 23 septembre 2024, ont été approuvés par le comité de rémunération du conseil d'administration de GeneDx en tant que primes d'incitation dans le cadre du Plan d'Incitation en Actions 2023 de l'entreprise.
Les RSUs seront attribuées par tranches annuelles égales sur quatre ans, sous réserve d'une continuité d'emploi. Chaque RSU représente le droit de recevoir une action de l'Action Ordinaire Classe A de GeneDx lors du règlement. Cette action est conforme à la Règle de Cotation Nasdaq 5635(c)(4), qui permet l'attribution d'actions aux nouveaux employés sans approbation des actionnaires.
GeneDx (Nasdaq: WGS), ein führendes Unternehmen für genomische Erkenntnisse zur Verbesserung der Gesundheitsresultate, hat die Gewährung von 7.700 eingeschränkten Aktieneinheiten (RSUs) für zwei neu eingestellte Mitarbeiter bekannt gegeben. Die Gewährungen, die ab 23. September 2024 wirksam sind, wurden vom Vergütungsausschuss des Vorstands von GeneDx als Anreizpreise im Rahmen des 2023 Equity Inducement Plans genehmigt.
Die RSUs werden in gleichen jährlichen Raten über vier Jahre fällig, abhängig von einer fortgesetzten Anstellung. Jede RSU repräsentiert das Recht, eine Aktie der GeneDx Klasse A Stammaktien bei der Abrechnung zu erhalten. Diese Maßnahme steht im Einklang mit der Nasdaq Listing Rule 5635(c)(4), die Aktienzuteilungen an neue Mitarbeiter ohne Zustimmung der Aktionäre erlaubt.
- Attraction of new talent through equity incentives
- Alignment of employee interests with company performance through RSU grants
- Potential dilution of existing shareholders' equity
The inducement RSUs will vest in equal annual installments over the four-year period following the grant date, subject to the employee’s continued service with the Company on each applicable vesting date. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240926347394/en/
Investor Relations:
investors@GeneDx.com
Media:
press@GeneDx.com
Source: GeneDx
FAQ
How many restricted stock units (RSUs) did GeneDx (WGS) grant to new employees on September 23, 2024?
What is the vesting schedule for the RSUs granted by GeneDx (WGS)?
Under which plan were the RSUs granted by GeneDx (WGS)?
What does each RSU represent for GeneDx (WGS) employees?
